We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

14 hedge funds and large institutions have $790K invested in Moleculin Biotech in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

27% more funds holding

Funds holding: 11 → 14 (+3)

10% more capital inflows, than outflows

Capital inflows: $109K | Capital outflows: $99.4K

1.59% less ownership

Funds ownership: 16.16% → 14.57% (-1.6%)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
+$66.6K
2
UBS Group
UBS Group
Switzerland
+$21.8K
3
LPL Financial
LPL Financial
California
+$12.1K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$4.85K
5
Bogart Wealth LLC
Bogart Wealth LLC
Virginia
+$1.21K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$98.1K
2
Atticus Wealth Management
Atticus Wealth Management
Florida
-$1.21K
3
Danske Bank
Danske Bank
Denmark
-$6
4
JP Morgan Chase
JP Morgan Chase
New York
-$3

MBRX Hedge Fund Activity: Q4 2024 in Review

14 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2024, worth a combined $790K — down 40% from $1.31M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new MBRX positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Armistice Capital, adding an estimated $66.6K. The largest seller was Vanguard Group, cutting an estimated $98.1K.

  • 14 institutional investors held Moleculin Biotech (MBRX) as of Q4 2024, up from 11 in Q3 2024.
  • Funds reported $790K of Moleculin Biotech stock for Q4 2024, down 40% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q4 2024 and 0 closed out, a net change of +3 holders.
  • The largest Moleculin Biotech buyer in Q4 2024 was Armistice Capital, an estimated $66.6K added.
  • The largest Moleculin Biotech seller in Q4 2024 was Vanguard Group, an estimated $98.1K sold.

Based on aggregated 13F filings for Q4 2024.